Immunisation practices of paediatric oncologists: An Australasian survey

被引:23
作者
Crawford, Nigel W.
Heath, John A.
Buttery, Jim P.
机构
[1] Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Med Genet, Immun Adverse Events Surveillance Unit, Parkville, Vic 3052, Australia
[2] Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Med Genet, Immun Serv, Parkville, Vic 3052, Australia
[3] NHMRC Ctr Clin Res Excellence Child & Adolescent, Parkville, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Royal Childrens Hosp, Childrens Canc Ctr, Melbourne, Vic, Australia
关键词
immunisation; oncology; paediatric; questionnaire; ACUTE LYMPHOBLASTIC-LEUKEMIA; INFLUENZA IMMUNIZATION; CHILDREN; CHEMOTHERAPY; COMPLETION; THERAPY; VACCINE; CANCER; RISK;
D O I
10.1111/j.1440-1754.2007.01162.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: The aim of this survey was to identify the current practices of paediatric oncologists in Australia and New Zealand regarding the immunisation of children treated for cancer. Methods: The survey was a nine-part questionnaire of current immunisation practices emailed to all paediatric oncologists practising in Australia (nine centres) and New Zealand (three centres) in June 2006. Results: Overall response rate was 82% (37 of 45 oncologists). Ninety-four per cent of respondents would recommend commencing 'booster' vaccinations at 6 months post completion of chemotherapy, in keeping with the current guidelines. Seventy-four per cent would recommend varicella vaccination. Intensity of the chemotherapy treatment was felt to be important, with 97% recommending re-immunising after a high-intensity regimen and only 48% after a lower-intensity regimen. Sixty-nine per cent stated they would recommend yearly influenza vaccinations for their patients. Conclusions: This survey highlights the variability of practice in Australasia; for example, nearly one-third do not recommend yearly influenza vaccination for their patients. The level of chemotherapy intensity was an important factor for paediatric oncologists in determining whether 'booster' vaccinations were recommended. This is an important cancer survivorship issue and review of the evidence-base and implementation of these guidelines is required.
引用
收藏
页码:593 / 596
页数:4
相关论文
共 15 条
[1]   Reimmunization after therapy for childhood cancer [J].
Chisholm, Julia C. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (05) :643-645
[2]  
CRAWFORD NW, IMM C 2006 SYDN AUST
[3]   RISK OF HAEMOPHILUS-INFLUENZAE TYPE-B DISEASE IN CHILDREN WITH CANCER AND RESPONSE OF IMMUNOCOMPROMISED LEUKEMIC CHILDREN TO A CONJUGATE VACCINE [J].
FELDMAN, S ;
GIGLIOTTI, F ;
SHENEP, JL ;
ROBERSON, PK ;
LOTT, L .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :926-931
[4]   Survey of influenza immunisation uptake in 'high risk' children [J].
Hale, K .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) :321-321
[5]   SEVERE MEASLES IN IMMUNOCOMPROMISED PATIENTS [J].
KAPLAN, LJ ;
DAUM, RS ;
SMARON, M ;
MCCARTHY, CA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (09) :1237-1241
[6]   Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies [J].
Lalazar, Gadi ;
Rund, Deborah ;
Shouval, Daniel .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (05) :699-712
[7]   Survey of immunisation practices in the United Kingdom during and following completion of anti-cancer chemotherapy in children [J].
Mahajan, A ;
English, MW ;
Jenney, ME ;
Foot, A .
MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 40 (04) :270-271
[8]  
*MIN HLTH, 2006, NZ IMM HDB
[9]   Live varicella vaccine in both immunocompromised and healthy children [J].
Morales-Castillo, ME ;
Alvarez-Muñoz, MT ;
Solórzano-Santos, F ;
González-Robledo, R ;
Jasso-Gutiérrez, L ;
Muñoz-Hernández, O .
ARCHIVES OF MEDICAL RESEARCH, 2000, 31 (01) :85-87
[10]  
*NHMRC, 2007, IN PRESS AUSTR IMM H, P71